Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
2141-2160 of 2,251 trials

Liver Surgery: Blood Clot Prevention Study

We are comparing two methods of preventing blood clots in patients undergoing liver resection. The goal is to find out which method is safer and more effective in reducing clot risks.

Liver SurgeryMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyHematologyOrthopedics and Traumatology

High-Dose Influenza Vaccine for Adults 60 and Older

We are studying a new high-dose flu vaccine to see if it provides better immune protection than a standard vaccine for adults aged 60 and above. The trial will also assess the safety of this new vaccine.

Influenza Immunization1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInfectious Diseases

Vitamin D3 Supplementation: Young Adults vs. Seniors

We are comparing how vitamin D3 affects young adults and seniors to find the best supplementation approach for each group. The study also examines how respiratory illnesses might influence vitamin D levels.

Healthy Participants1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesAllergologyDermatologyEndocrinologyInfectious DiseasesInternal MedicineNephrologyOphthalmologyOtolaryngologyPediatricsPsychiatryPulmonology

Chronic Rhinosinusitis with Nasal Polyps: Tapering Biologics

We are studying whether patients with stable chronic rhinosinusitis can safely reduce their biologic medication dosage after a year. This trial compares the effects of Mepolizumab and Dupilumab on disease control.

Chronic Rhinosinusitis with Nasal Polyps1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesAllergologyOtolaryngology

Metastatic Uveal Melanoma: Liver Radiotherapy with Tebentafusp

We are studying if adding liver-directed radiotherapy to the standard treatment helps patients with metastatic uveal melanoma live longer and stay on treatment longer. This trial also looks at how the body responds to the combination therapy.

Metastatic Uveal MelanomaEfficacy phase (II)No PlaceboStandard MedicinesHepatologyOncology

Anal High-Grade Lesions: Sinecatechins Ointment

We are studying whether adding a topical ointment to standard treatment helps patients with high-grade anal lesions achieve better results. The goal is to see if it reduces lesions and prevents recurrence.

Anal High-Grade Squamous Intraepithelial Lesions (HSIL)1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Rezafungin for Fungal Infections in Critically Ill Patients

We are studying how Rezafungin levels change in patients on ECMO, a life-support treatment. This research aims to understand its effectiveness and any potential side effects.

Invasive Candidiasis>2 yearsConfirmation phase (III)Monitoring phase (IV)16-20 visitsNo PlaceboStandard MedicinesInfectious DiseasesInternal MedicinePulmonology

Non-Small Cell Lung Cancer: BMS-986504 Treatment Study

We are evaluating a new medication for patients with advanced non-small cell lung cancer who have a specific genetic deletion. The study aims to understand how well it works and its safety compared to previous treatments.

Advanced or Metastatic Non-small Cell Lung CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPulmonology

Narcolepsy and Idiopathic Hypersomnia: ALKS 2680 Study

We are investigating the safety and tolerability of ALKS 2680 for people with narcolepsy and idiopathic hypersomnia. The study also looks at its effects on excessive daytime sleepiness and cataplexy.

Narcolepsy and Idiopathic Hypersomnia>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Multiple Myeloma: Comparing Treatment Approaches

We are studying two treatment plans for newly diagnosed multiple myeloma patients who cannot have a transplant. Our goal is to see which plan helps more patients reach a state of minimal disease.

Multiple MyelomaConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Chronic Heart Failure: Vitamin D and Oral Iron Study

We are studying whether vitamin D combined with oral iron can improve symptoms in patients with chronic heart failure and iron deficiency. This trial compares it to standard intravenous iron treatment to see which is more effective.

Chronic Heart FailureIron Deficiency3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Non-Small Cell Lung Cancer: QL2107 vs. Keytruda®

We are comparing a new treatment, QL2107, to Keytruda® for patients with resected non-small cell lung cancer. The study aims to see if QL2107 works similarly in the body and to evaluate its safety and immune response.

Non-small Cell Lung Cancer1-2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

PM14 Treatment for Soft Tissue Sarcomas and Solid Tumors

We are studying how PM14 works alone and with radiotherapy in patients with soft tissue sarcomas and other solid tumors. The goal is to find the best treatment approach and understand its safety and effectiveness.

Soft Tissue Sarcomas and Other Solid Tumors6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncologyOrthopedics and Traumatology

Momelotinib for Anemia in Low-Risk Myelodysplastic Syndrome

We are studying whether momelotinib can improve red blood cell counts in patients with low-risk myelodysplastic syndrome. The trial also looks at the safety of this treatment.

Myelodysplastic Syndrome3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Metastatic Colorectal Cancer: Fruquintinib and Tislelizumab Study

We are studying a new treatment combining Fruquintinib and Tislelizumab for patients with metastatic colorectal cancer without active liver metastases. The goal is to evaluate its effectiveness and safety while also assessing quality of life.

Metastatic Colorectal Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Cerebrospinal Fluid Disorders: MRI Contrast Agent Study

We are testing a new MRI contrast agent to assess cerebrospinal fluid flow in adults with CSF disorders. This may help improve diagnosis and treatment of central nervous system conditions.

Idiopathic Intracranial HypertensionIntracranial CystsPrimary or Secondary Brain Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyOtolaryngology

Type 1 Diabetes: Once-Weekly Insulin Icodec vs. Daily Insulin Glargine

We are studying whether a new once-weekly insulin can help adults with type 1 diabetes manage their blood sugar levels as well as the standard daily insulin. This trial will also look at safety and patient experiences.

Type 1 Diabetes6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesDiabetologyEndocrinology

CART84 Treatment for Relapsed Acute Leukemias

We are studying a new infusion treatment called CART84 for patients with relapsed or refractory acute myeloid leukemia and acute lymphoblastic T leukemia. The goal is to evaluate its safety and effectiveness in helping patients achieve remission.

Relapsed/Refractory Acute Lymphoblastic T Leukemia (T-ALL)Relapsed/Refractory Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Infective Endocarditis: Oral vs. Parenteral Antibiotics

We are comparing oral antibiotics to outpatient parenteral antibiotics for treating infective endocarditis. The goal is to see if oral treatment is as effective and to assess patient satisfaction and costs.

Infective Endocarditis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInfectious Diseases

Rheumatoid Arthritis: Lower Dose of Rituximab Study

We are evaluating whether a 200 mg dose of Rituximab every six months is as effective as the standard 1 g dose for managing rheumatoid arthritis. This study will help us understand its impact on disease activity and overall patient well-being.

Rheumatoid Arthritis>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementRheumatology